Phase 2 Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults between 18 and 75 years old, of any gender
• People whose lung cancer has been confirmed by tissue testing to be a type called lung adenocarcinoma, which cannot be removed by surgery or cured with radiation, and has either spread locally or to other parts of the body
• People whose cancer has been confirmed by a local lab to have a specific gene change (mutation) in the EGFR gene — either the "19Del" or "L858R" type
• People who have not yet received any systemic (whole-body) anti-cancer treatment for their advanced or metastatic lung cancer
• People who have at least one tumour that can be measured using standard imaging criteria
• People who have been confirmed to have cancer that has spread to both the brain tissue and the lining surrounding the brain (called the meninges) at the same time
• People whose blood test results show that their bone marrow, liver, and kidneys are functioning well enough to meet specific levels set by the trial (confirm exact values with trial site)
• People whose general health and ability to carry out daily activities falls within a certain range on a standard scale (called ECOG score 0–2), with no significant worsening in the two weeks before entering the trial
• People whose doctors expect them to live for more than 12 weeks
• Women of childbearing age who are not pregnant and do not plan to become pregnant, and both women of childbearing age and men who agree to use effective contraception during the trial and for 6 months after stopping the trial treatment
• People who understand the study, are willing to take part voluntarily, and have signed a consent form

Who may not be able to join:

• People whose lung cancer is mainly of a type called squamous cell, or who have small cell lung cancer, neuroendocrine carcinoma, or similar types
• People whose cancer is driven by certain other gene mutations, such as ALK, ROS1, RET, BRAF, NTRK, MET, or KRAS (note: having changes in TP53, RB1, or BRCA does not exclude someone — confirm with trial site)
• People who are expected to need other anti-cancer treatments during the trial period, beyond what the trial provides
• People who have had any of the following: major surgery within 4 weeks before starting the trial; certain medications that strongly affect how drugs are processed by the liver (called strong CYP3A4 inhibitors or inducers) taken within a specific timeframe before starting; certain Chinese herbal medicines with anti-cancer purposes taken within 2 weeks before starting; participation in another clinical trial within 4 weeks (or within 5 half-lives of the other trial drug, whichever is longer); or other anti-cancer drugs taken within 14 days before starting
• People with fluid build-up around the lungs or abdomen that is causing symptoms and is not yet stable — though people who have had the fluid drained and have been stable for at least 14 days may still be considered
• People who still have significant side effects from previous cancer treatments that have not yet improved to a mild level (with the exception of hair loss or certain nerve-related effects from previous platinum-based chemotherapy)
• People who have, or have had, another type of cancer, unless it was completely removed more than 5 years ago with no return — certain low-risk cancers such as cervical carcinoma in situ, basal cell skin cancer, or papillary thyroid cancer may be exceptions (confirm with trial site)
• People with a history of a lung condition called interstitial lung disease, or lung inflammation from medication or radiation that required steroid treatment, or who currently show signs suggesting this condition
• People with serious or poorly controlled health conditions such as high blood pressure, diabetes, severe heart failure, unstable chest pain, a heart attack within the past year, active bleeding, severe digestive problems, or active infections
• People whose heart's electrical activity shows a specific measurement (QTc interval) above 470 milliseconds on an ECG, or who have other heart rhythm problems that may increase certain risks
• People with a known history of psychiatric disorders or drug misuse where symptoms or drug use are currently active
• People who are known or suspected to be allergic to the trial drug (furmonertinib) or any of its ingredients
• Women who are pregnant or breastfeeding, or female partners of male participants who plan to become pregnant during the study period
• People who the trial team considers unlikely to follow the trial requirements reliably
• People whom the trial investigator considers unsuitable for any other reason

Important: Always verify eligibility with the trial site directly before applying.